Process Validation Guidance Requirements (FDA and EU Annex 15

  • Check with publisher
  • Published date: May 15, 2021
    • san Jose, california, United States

The Process Validation Guidelines (January 2011) and the EU Annex 15: Qualification and Validation (October 2015) outline the general principles and approaches the two regulatory bodies consider appropriate elements of process validation for the manufacture of human and animal drugs and biological products, including Active Pharmaceutical Ingredients (APIs). These guidances align Process Validation activities with a product lifecycle concept and with existing FDA and EU guidances, including the FDA/International Conference on Harmonization (ICH), Guidance for Industry, Q8 (R2) Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System. The lifecycle concept, new to these Guidances, link product and process development, qualification of the commercial manufacturing process, and maintenance of the process in a state of control during routine commercial production. These guidances also support process improvement and innovation through sound science and risk management. The new Process Validation Guideline/Practice incorporate elements of Process Validation as early as the Research and Development phase, and continues onward through Technology Transfer, into the Phase 1 IND Clinical Trial manufacturing phase, and ultimately into Phase 2 and 3, and then commercial manufacturing.

Result 0 votes
Ashutos Swain
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Quality and GMP Compliance for Virtual Companies (Pharmaceutical and Biologics Industries)

    Quality and GMP Compliance for Virtual Companies (Pharmaceutical and Biologics Industries)

    Pharmacology - Drug Development san Jose (california) May 15, 2021 Check with publisher

    Today, many companies operate on an outsourcing model. This is very common for companies who are evolving from being mainly development-focused to a point where they are entering latter stages of Phase 2 or Phase 3 clinical trials, and plan to have a...

  • How to write SOP's that Avoid Human Error

    How to write SOP's that Avoid Human Error

    Pharmacology - Drug Development san Jose (california) May 13, 2021 Check with publisher

    Human error is known to be the primary cause of quality and production losses in many industries. Although it is unlikely that human error will ever be eliminated, many human performance problems can be prevented. Human errors start at the design sta...

  • Change Control Best Practices - Avoiding Unintended Consequences of Changes

    Change Control Best Practices - Avoiding Unintended Consequences of Changes

    Pharmacology - Drug Development san Jose (california) April 20, 2021 Check with publisher

    This seminar will help all personnel involved in proposing, assessing, and implementing changes to understand and successfully apply Change Control best practices. Key focus will be placed on change proposals, justification / risk assessment and chan...